TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36309950

Group type: EXPERIMENTAL
Intervention: Carbidopa 50 mg with 100 mg IR levodopa and 200 mg entacapone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbidopa 100 mg with 100 mg IR levodopa and 200 mg entacapone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbidopa 50 mg with 100 mg IR levodopa without entacapone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbidopa 100 mg with 100 mg IR levodopa without entacapone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbidopa doses with 200 mg entacapone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Carbidopa doses
Number of subjects: 25
Study: 34937710

Group type: EXPERIMENTAL
Intervention: Doctor wearing a white coat
Number of subjects: 286

Group type: COMPARATOR
Intervention: Doctor not wearing a white coat
Number of subjects: 286
Study: 36355846

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia at the first day of ascent (HH1)
Number of subjects: 20
Study: 32601329

Group type: EXPERIMENTAL
Intervention: Continuous suture
Number of subjects: 134

Group type: COMPARATOR
Intervention: Interrupted suture
Number of subjects: 134
Study: 35446415

Group type: EXPERIMENTAL
Intervention: Substantive Cognitive Impairment (SCI)
Number of subjects: 8772

Group type: EXPERIMENTAL
Intervention: Cognitive Impairment based on geometric mean (SCI-GM)
Number of subjects: 8772
Study: 33450160

Group type: EXPERIMENTAL
Intervention: Robotic adrenalectomy (RA-g)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Laparoscopic adrenalectomy (LA-g)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Robotic left adrenalectomy
Number of subjects: 160
Study: 32184033

Group type: EXPERIMENTAL
Intervention: anti-gE ELISA
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: anti-VZV ELISA
Number of subjects: 397
Study: 35597947

Group type: EXPERIMENTAL
Intervention: TRIP intervention (patient navigation intervention)
Number of subjects: 17
Study: 34716902

Group type: EXPERIMENTAL
Intervention: RIST4721 300 mg once daily for 28 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 34028170

Group type: EXPERIMENTAL
Intervention: mini‐PCNL
Number of subjects: 67

Group type: COMPARATOR
Intervention: ESWL
Number of subjects: 67
Study: 32907635

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin
Number of subjects: 1000
Study: 35768027

Group type: EXPERIMENTAL
Intervention: Urologists' recommendations (surgery)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Radiation oncologists' recommendations (radiation)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Concordance between recommendations
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Treatment received by patients
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Discordant recommendations
Number of subjects: 108
Study: 33328285

Group type: EXPERIMENTAL
Intervention: AT247
Number of subjects: 19
Study: 36429962

Group type: EXPERIMENTAL
Intervention: Integral‐CARE Interdisciplinary Program (IP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 32844483

Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 207

Group type: COMPARATOR
Intervention: 1% cyclopentolate
Number of subjects: 207
Study: 35636787

Group type: EXPERIMENTAL
Intervention: LifeBuoy application
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: LifeBuoy+engagement
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo app (attention-matched control)
Number of subjects: 669
Study: 32945860

Group type: EXPERIMENTAL
Intervention: Gamified ICTs (42 daily and 2 weekly sessions)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nongamified ICTs (42 daily and 2 weekly sessions)
Number of subjects: 76
Study: 32583468

Group type: EXPERIMENTAL
Intervention: Amplitude-based gating (AG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Count-based gating (CG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Phase or time-based gating (TG)
Number of subjects: 15
Study: 36440473

Group type: EXPERIMENTAL
Intervention: Intrathecal drug delivery (IDD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 54
Study: 33448607

Group type: EXPERIMENTAL
Intervention: LATP biopsy
Number of subjects: 1218
Study: 35355249

Group type: EXPERIMENTAL
Intervention: KHKi 50 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: KHKi 280 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: KHKi alone (100–600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atorvastatin alone (20 mg single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Model-based analysis
Number of subjects: 12
Study: 34428929

Group type: EXPERIMENTAL
Intervention: ACEI treatment
Number of subjects: 177

Group type: COMPARATOR
Intervention: ARB treatment
Number of subjects: 177

Group type: COMPARATOR
Intervention: non-ACE/ARB treatment
Number of subjects: 177
Study: 34396911

Group type: EXPERIMENTAL
Intervention: LEF plus low-dose prednisone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 108
Study: 32242018

Group type: EXPERIMENTAL
Intervention: Serotonin-norepinephrine reuptake inhibitor (SNRI) treatment
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: GPR56 peptide agonists
Number of subjects: 424

Group type: COMPARATOR
Intervention: Gpr56 knockdown in mouse PFC
Number of subjects: 424
Study: 35199834

Group type: EXPERIMENTAL
Intervention: 1000 mg/d DHA (experimental group: EXP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 200 mg/d DHA (standard group: STD)
Number of subjects: 9
Study: 34414609

Group type: EXPERIMENTAL
Intervention: Ensemble machine learning model
Number of subjects: 33657

Group type: COMPARATOR
Intervention: Random forest
Number of subjects: 33657

Group type: COMPARATOR
Intervention: Deep neural network
Number of subjects: 33657

Group type: COMPARATOR
Intervention: Logistic regression
Number of subjects: 33657

Group type: COMPARATOR
Intervention: Adaboost
Number of subjects: 33657
Study: 32907614

Group type: EXPERIMENTAL
Intervention: MTX+pred
Number of subjects: 92

Group type: COMPARATOR
Intervention: MTX+plac
Number of subjects: 92
Study: 36185549

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg plus topical corticosteroids (TCS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg plus topical corticosteroids (TCS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo plus topical corticosteroids (TCS)
Number of subjects: 29
Study: 36105447

Group type: EXPERIMENTAL
Intervention: Omaha system continuous nursing intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine postoperative nursing intervention
Number of subjects: 76
Study: 32166837

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: No continuous positive airway pressure (Control)
Number of subjects: 72
Study: 36074627

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine lozenge
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 67
Study: 34391301

Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Muscle energy (ME) technique
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 32843762

Group type: EXPERIMENTAL
Intervention: D-Tagatose and Xylitol (combined)
Number of subjects: 29

Group type: COMPARATOR
Intervention: D-Tagatose
Number of subjects: 29

Group type: COMPARATOR
Intervention: Xylitol
Number of subjects: 29
Study: 35320214

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33308328

Group type: EXPERIMENTAL
Intervention: Millet couscous (self-made)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Millet foods (millet couscous, millet thick porridge) and wheat couscous
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All foods tested (millet couscous, millet thick porridge, wheat couscous, white rice)
Number of subjects: 14
Study: 32198095

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no TENS)
Number of subjects: 60
Study: 35768708

Group type: EXPERIMENTAL
Intervention: Bioheart Sirolimus-Eluting Bioresorbable Vascular Scaffold (BRS)
Number of subjects: 46
Study: 34941547

Group type: EXPERIMENTAL
Intervention: QualityIQ tool (gamified approach)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-CME study arm
Number of subjects: 120
Study: 35909264

Group type: EXPERIMENTAL
Intervention: Riociguat (0.5 mg TID up-titrated to 1.5 mg TID)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 114
Study: 32394733

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 153
Study: 32060506

Group type: EXPERIMENTAL
Intervention: 4-hour introductory training intervention
Number of subjects: 34
Study: 35411924

Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (SYN) containing inulin (4 g) and Lactobacillus rhamnosus GG (>1 × 10^7 CFU/mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control yogurt (CON)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (SYN)
Number of subjects: 30
Study: 35172560

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (RM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Rituximab injections
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hypogammaglobulinemia <6 g/L or <4 g/L
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Hypogammaglobulinemia
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Infectious events, neutropenia, and CD4 lymphopenia
Number of subjects: 240
Study: 32518101

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 45
Study: 35650426

Group type: EXPERIMENTAL
Intervention: Initial imatinib therapy
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Predictive scoring systems for MMR and MR4
Number of subjects: 1369
Study: 32975880

Group type: EXPERIMENTAL
Intervention: Bare arm
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Single-layer cotton shirt sleeve (1 mm)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Two layers sleeve (cotton shirt and polar fabric sweater, 3 mm)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Two layers sleeve (cotton shirt and thick cardigan, 4 mm)
Number of subjects: 300
Study: 33099298

Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase (ALP) levels
Number of subjects: 14393
Study: 35230558

Group type: EXPERIMENTAL
Intervention: Positional change (raised legs position)
Number of subjects: 31

Group type: COMPARATOR
Intervention: PEEP
Number of subjects: 31

Group type: COMPARATOR
Intervention: Phenylephrine infusion
Number of subjects: 31
Study: 33140685

Group type: EXPERIMENTAL
Intervention: Endovascular and surgical cardiovascular procedures
Number of subjects: 852
Study: 34127095

Group type: EXPERIMENTAL
Intervention: Cariprazine (3-12 mg/d, 3-6 mg/d, or 6-12 mg/d for 3 weeks)
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012
Study: 34766785

Group type: EXPERIMENTAL
Intervention: smartphone breathalyzer device/app
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: app that estimates BAC based on factors including sex, weight, number/types of drinks over time
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: self-text messaging after each drink
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: combined mobile technology intervention
Number of subjects: 99

Group type: COMPARATOR
Intervention: laboratory alcohol self-administration
Number of subjects: 99
Study: 33275087

Group type: EXPERIMENTAL
Intervention: Video-assisted modified LIFT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Incision thread drawing
Number of subjects: 60
Study: 35182042

Group type: COMPARATOR
Intervention: Intramuscular (IM) galidesivir, doses 0.3 to 10 mg/kg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Intravenous (IV) galidesivir, doses 5 to 20 mg/kg
Number of subjects: 126

Group type: COMPARATOR
Intervention: IM galidesivir with lidocaine, single day dosing and 7-day dosing
Number of subjects: 126

Group type: COMPARATOR
Intervention: IV galidesivir, single ascending doses
Number of subjects: 126
Study: 32770757

Group type: EXPERIMENTAL
Intervention: Extended release naltrexone (XR‐NTX)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 35
Study: 36343645

Group type: EXPERIMENTAL
Intervention: BI 187004 (10-360 mg once daily for 14 days)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: BI 187004 (≥40 mg once daily for 14 days)
Number of subjects: 71
Study: 35634085

Group type: EXPERIMENTAL
Intervention: Tendon bone setting technique combined with sports training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermediate frequency electrotherapy combined with forearm brace fixation
Number of subjects: 50
Study: 32681304

Group type: EXPERIMENTAL
Intervention: Enhanced survivorship care plan (ESCP) with a link to Patient Education Resources for Couples (PERC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard survivorship care plan (SCP) with a link to general PC information
Number of subjects: 62
Study: 32046452

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily + COC containing drospirenone for 21 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: COC containing drospirenone for 21 days + placebo
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo similar to COC + placebo similar to fluoxetine
Number of subjects: 300
Study: 35926795

Group type: EXPERIMENTAL
Intervention: Periarticular Injection (PAI)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PAI + Patient‐Controlled Epidural Analgesia (PCEA) with 0.06% bupivacaine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Patient‐Controlled Epidural Analgesia (PCEA) without intrathecal opioids
Number of subjects: 180
Study: 33440017

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 625
Study: 32201400

Group type: EXPERIMENTAL
Intervention: Nori (dried laver) - 1.76 grams per day for 10 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group - usual diet
Number of subjects: 89
Study: 33205362

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg with ethanol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Daridorexant 50 mg alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ethanol alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 34932140

Group type: EXPERIMENTAL
Intervention: SMaRT group intervention (10-week symptom-management intervention including group support, education, pelvic floor muscle exercises)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SMaRT group intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Care-as-usual group
Number of subjects: 63
Study: 33576510

Group type: EXPERIMENTAL
Intervention: DVI model
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: dosiomic model
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: hybrid model
Number of subjects: 247
Study: 32621045

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 4672
Study: 34651611

Group type: EXPERIMENTAL
Intervention: Wearing surgical mask (SM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No surgical mask (no-SM)
Number of subjects: 33
Study: 34531206

Group type: EXPERIMENTAL
Intervention: Quick-Wee method (suprapubic stimulation with cold saline-soaked gauze)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Bladder stimulation (pubic tapping alternating with lumbar massage)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Quick-Wee method
Number of subjects: 230

Group type: COMPARATOR
Intervention: Bladder stimulation
Number of subjects: 230
Study: 34098009

Group type: EXPERIMENTAL
Intervention: Tablet-delivered cognitive-motor program (120 min per week balance, strength and cognitive training)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (received monthly phone calls and health fact sheets)
Number of subjects: 93
Study: 32184086

Group type: EXPERIMENTAL
Intervention: Autotransplanted teeth with open apices
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuation of root development during follow-up
Number of subjects: 36

Group type: COMPARATOR
Intervention: Distant transplantations
Number of subjects: 36

Group type: COMPARATOR
Intervention: 1-rooted teeth
Number of subjects: 36

Group type: COMPARATOR
Intervention: Premolars
Number of subjects: 36

Group type: COMPARATOR
Intervention: Teeth not stored in extraoral media
Number of subjects: 36

Group type: COMPARATOR
Intervention: Teeth transplanted later during the study period
Number of subjects: 36
Study: 33319753

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 1114

Group type: COMPARATOR
Intervention: 10% povidone-iodine
Number of subjects: 1114
Study: 36101806

Group type: EXPERIMENTAL
Intervention: CBL teaching mode
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 32762161

Group type: EXPERIMENTAL
Intervention: letrozole and spironolactone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: gonadotrophin releasing hormone analogue (GnRHa)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: letrozole and GnRHa
Number of subjects: 75
Study: 35487229

Group type: EXPERIMENTAL
Intervention: Safer gambling message condition (yellow version)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Safer gambling message condition
Number of subjects: 1509
Study: 35606739

Group type: EXPERIMENTAL
Intervention: Carbon ion therapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Photon or proton radiotherapy
Number of subjects: 250
Study: 33166858

Group type: EXPERIMENTAL
Intervention: Gelfoam packing (GPG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-gelfoam packing (NGPG)
Number of subjects: 57
Study: 33678106

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at weeks 0, 4, 16, and 28
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 4
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 16
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: PASI <50 at week 16
Number of subjects: 575
Study: 34479640

Group type: EXPERIMENTAL
Intervention: Culturally adapted BREATHE intervention for PTSD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37103690

Group type: EXPERIMENTAL
Intervention: Hydroquinone 4% plus nitrogen plasma therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroquinone 4% alone (Control)
Number of subjects: 0
Study: 32958487

Group type: EXPERIMENTAL
Intervention: Go Wish intervention for patients and their relatives
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Go Wish intervention for patients alone
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standardised information on advance directives (usual care)
Number of subjects: 135
Study: 35483387

Group type: EXPERIMENTAL
Intervention: Natalizumab once every 6 weeks
Number of subjects: 499

Group type: COMPARATOR
Intervention: Natalizumab once every 4 weeks
Number of subjects: 499
Study: 33753120

Group type: EXPERIMENTAL
Intervention: Electronic hand hygiene monitoring systems (EHHMSs)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-quality stepped-wedge cluster randomized controlled trial design
Number of subjects: 5

Group type: COMPARATOR
Intervention: General EHHMS implementation
Number of subjects: 5
Study: 35133057

Group type: EXPERIMENTAL
Intervention: Progressive Resistance and Balance Training (PRBT) for 26 weeks
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 245
Study: 33097414

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus BSC
Number of subjects: 420

Group type: COMPARATOR
Intervention: BSC
Number of subjects: 420
Study: 35167999

Group type: EXPERIMENTAL
Intervention: Prickly Pear juice (250 mL; 45 mg betalain content; reduced fiber)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo drink (water-based)
Number of subjects: 17
Study: 33711412

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 33038062

Group type: EXPERIMENTAL
Intervention: E6011 100 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: E6011 200 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: E6011 400/200 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: E6011 100 mg (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: E6011 200 mg (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: E6011 400/200 mg (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (in subgroup with higher baseline CD16+ monocytes)
Number of subjects: 190
Study: 32521358

Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program (4-week, 3 sessions per week via videoconference)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program
Number of subjects: 162